ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Regulatory news

EU · CHMP positive opinion

Ensartinib (Gevalka)

The treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC)

Randomised trials of this medicine for this use, found by Y in PubMed (the regulator's assessment may rest on other studies too):

In 274 patients with resected ALK-positive stage IB–IIIB NSCLC after adjuvant chemotherapy, 24 months of ensartinib vs placebo raised 24-month disease-free survival in stage II–IIIB disease (86.4% vs 53.5%; HR 0.20). Grade ≥3 adverse events: 35.8% vs 18.2%. RCT · phase 3 · n = 274 · N Engl J Med · 2026

1 trial is being summarised and will appear here shortly.

CHMP opinion 17 Sept 2026 · SFL Pharmaceuticals Deutschland GmbH

Research

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.